These results highlight IL-4’s central role in cancer-associated immunosuppression and introduce a promising new therapy combining immune checkpoint inhibitors with cytokine-blocking strategies, suggesting a systemic approach to cancer treatment [127]. This evidence concerns the gene IL4 and cancer.